[go: up one dir, main page]

AUPR688101A0 - Protein domains and their ligands - Google Patents

Protein domains and their ligands

Info

Publication number
AUPR688101A0
AUPR688101A0 AUPR6881A AUPR688101A AUPR688101A0 AU PR688101 A0 AUPR688101 A0 AU PR688101A0 AU PR6881 A AUPR6881 A AU PR6881A AU PR688101 A AUPR688101 A AU PR688101A AU PR688101 A0 AUPR688101 A0 AU PR688101A0
Authority
AU
Australia
Prior art keywords
ligands
protein domains
domains
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPR6881A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luminis Pty Ltd
Original Assignee
Luminis Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luminis Pty Ltd filed Critical Luminis Pty Ltd
Priority to AUPR6881A priority Critical patent/AUPR688101A0/en
Publication of AUPR688101A0 publication Critical patent/AUPR688101A0/en
Priority to PCT/AU2002/001064 priority patent/WO2003013523A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AUPR6881A 2001-08-08 2001-08-08 Protein domains and their ligands Abandoned AUPR688101A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AUPR6881A AUPR688101A0 (en) 2001-08-08 2001-08-08 Protein domains and their ligands
PCT/AU2002/001064 WO2003013523A1 (en) 2001-08-08 2002-08-08 Sh3 protein domains and their ligands

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR6881A AUPR688101A0 (en) 2001-08-08 2001-08-08 Protein domains and their ligands

Publications (1)

Publication Number Publication Date
AUPR688101A0 true AUPR688101A0 (en) 2001-08-30

Family

ID=3830837

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPR6881A Abandoned AUPR688101A0 (en) 2001-08-08 2001-08-08 Protein domains and their ligands

Country Status (2)

Country Link
AU (1) AUPR688101A0 (en)
WO (1) WO2003013523A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4613157B2 (en) 2003-01-14 2011-01-12 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
CA2547518A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
WO2005087775A1 (en) * 2004-03-15 2005-09-22 Ono Pharmaceutical Co., Ltd. Tricyclic heterocyclic compound and medicinal composition containing the compound as active ingredient
PL216049B1 (en) 2004-06-17 2014-02-28 Cytokinetics Inc Urea derivatives, compositions containing urea derivatives as well as the application of urea derivatives in the production of medications used to treat systolic heart failure
EP1781637A1 (en) * 2004-06-29 2007-05-09 Rigel Pharmaceuticals, Inc. 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
EP1917245A1 (en) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-ht5 receptors
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070161617A1 (en) 2005-12-15 2007-07-12 Morgan Bradley P Certain chemical entities, compositions and methods
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP5178526B2 (en) 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
US9513296B2 (en) 2006-08-21 2016-12-06 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
US9689879B2 (en) 2006-08-21 2017-06-27 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP2108644B1 (en) * 2006-11-24 2016-07-20 AC Immune S.A. N-(Methyl)-pyridin-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
CN101765591B (en) * 2007-07-26 2013-11-27 诺华股份有限公司 Pyrimidine derivatives useful for treatment of inflammatory or allergic conditions
MX2010003759A (en) 2007-10-09 2010-04-21 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators.
EP2062578A1 (en) 2007-11-12 2009-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel use of chemical compounds for the treatment of AIDS
JP2012529535A (en) 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー Nicotinamide compounds useful as kinase modulators
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
US9242975B2 (en) 2012-01-13 2016-01-26 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
JP6096219B2 (en) 2012-01-13 2017-03-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Triazolyl or triasiazolyl substituted pyridyl compounds useful as kinase inhibitors
CN104169275B (en) 2012-01-13 2017-06-09 百时美施贵宝公司 The pyridine compounds of the triazole substitution as kinase inhibitor
ES2616812T3 (en) 2012-11-08 2017-06-14 Bristol-Myers Squibb Company Pyridyl compounds substituted with bicyclic heterocycle useful as kinase modulators
CA2890983A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
CA2891412A1 (en) 2012-11-20 2014-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
EP2970199A1 (en) 2013-03-11 2016-01-20 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
UY35935A (en) 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware NICOTINAMIDE COMPOUNDS REPLACED WITH HETEROARILO AS QUINASE INHIBITORS AND MODULATORS OF IRAK-4
JP6800872B2 (en) * 2015-03-06 2020-12-16 ファーマケア，インク． Lysyl oxidase-like 2 inhibitor and its use
UY36748A (en) 2015-06-24 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware AMINOPIRIDINE COMPOUNDS REPLACED WITH HETEROARILO AS QUINASE INHIBITORS AND IRAK-4 MODULATORS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN109641906B (en) 2015-06-24 2021-10-01 百时美施贵宝公司 Heteroaryl-substituted aminopyridine compounds
ES2822956T3 (en) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Heteroaryl substituted aminopyridine compounds
ES2846833T3 (en) 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv PET imaging ligands
ES2889926T3 (en) 2017-05-11 2022-01-14 Bristol Myers Squibb Co Thienopyridines and benzothiophenes useful as IRAK4 inhibitors
JP7620611B2 (en) 2019-07-18 2025-01-23 ブリストル－マイヤーズ スクイブ カンパニー PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS - Patent application
EP3999508B1 (en) 2019-07-18 2023-08-30 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
CN114174304B (en) 2019-07-23 2024-05-17 百时美施贵宝公司 Thienopyridinyl and thiazolopyridinyl compounds useful as IRAK4 inhibitors
EP4010317B1 (en) 2019-08-06 2024-06-19 Bristol-Myers Squibb Company Bicyclic heterocyclic compounds useful as irak4 inhibitors
CN113121658B (en) * 2020-01-15 2022-10-21 中国农业大学 Gene of protein containing SH3 structural domain in rhizobium and related biological material and application thereof
CN115335380B (en) 2020-02-03 2024-08-02 百时美施贵宝公司 Tricyclic heteroaryl compounds useful as IRAK4 inhibitors
US12391702B2 (en) 2020-02-03 2025-08-19 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1169038E (en) * 1999-04-15 2012-10-26 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
WO2003013523A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
AUPR688101A0 (en) Protein domains and their ligands
AU2002310497A1 (en) Protein aggregation assays and uses thereof
AU6058500A (en) Fusion protein and uses thereof
AU2001251358A1 (en) Prion-binding ligands and methods of using same
AU5340399A (en) Proteases and associated proteins
AU2001274566A1 (en) Novel protein and dna thereof
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU2002312373A1 (en) Structural and cytoskeleton-associated proteins
AU2002306077A1 (en) Regulatory protein involved in pectin modification
AU2136401A (en) P450rai-2 and related proteins
AU2002357934A1 (en) Humanized lactoferrin and uses thereof
AU2001280993A1 (en) Tissue-associated proteins and their uses
AU2001244863A1 (en) Apoptin-associating protein
AU2002254314A1 (en) Trans inteins for protein domain shuffling and biopolymerization
AU3411999A (en) Novel rnase-like protein and its use
AU2002319011A1 (en) Sh3 protein domains and their ligands
AU2002240921A1 (en) Medane genes and proteins
AU2002316348A1 (en) Chimeric capsid proteins and uses thereof
AU2002320621A1 (en) Structural and cytoskeleton-associated proteins
AU2001250047A1 (en) Effector-specific protein assembly and uses thereof
AU2001234150A1 (en) Novel protein and gene encoding the same
GB0102447D0 (en) Protein variants and uses thereof
AU2002357609A1 (en) Novel proteins and dnas thereof
AU2001278777A1 (en) Irap-binding protein
AU2002230137A1 (en) Novel protein and use thereof